These results recapitulated the results observed from the intact cancer cell lines and suggest that ibrutinib is highly potent against EGFR (L858R) and EGFR (Del 19) mutations, however moderately active when the T790M gatekeeper mutation is introduced. The gene discussed is EGFR; the disease is cancer.